Evidence map›Paper›PMID 41995433›Full record

ArticleBritish journal of clinical pharmacology2026

The interplay of GLP-1 receptor agonist use, chronic kidney disease and fracture risk in obese pAtients: a retrospective cohort study.

Amari Eubanks, Kiana C Allen, Dy' Quan Kearney, Brieanna Bell, Anthony Albornoz, Rawan Elkomi, Damon Ross, Elizabeth Beyene, Mekdem Bisrat, Syed Fahad Gillani and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Amari EubanksHoward University College of Medicine, Washington, DC, USA.ORCID https://orcid.org/0009-0007-0797-4931
Kiana C AllenHoward University College of Medicine, Washington, DC, USA.ORCID https://orcid.org/0009-0009-1182-5749
Dy' Quan KearneyHoward University College of Medicine, Washington, DC, USA.ORCID https://orcid.org/0009-0001-0375-855X
Brieanna BellHoward University College of Medicine, Washington, DC, USA.ORCID https://orcid.org/0009-0001-0599-6025
Anthony AlbornozHoward University College of Medicine, Washington, DC, USA.ORCID https://orcid.org/0009-0007-1130-5239
Rawan ElkomiDepartment of Internal Medicine, Howard University, Washington, DC, USA.
Damon RossHoward University College of Medicine, Washington, DC, USA.ORCID https://orcid.org/0009-0004-1337-9168
Elizabeth BeyeneDepartment of Internal Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Mekdem BisratDepartment of Internal Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Syed Fahad GillaniDepartment of Internal Medicine, Howard University, Washington, DC, USA.
Miriam MichaelDepartment of Internal Medicine, Howard University, Washington, DC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate the association between Glucagon-like peptide-1 receptor agonist (GLP-1RA) use and fracture risk in patients with or without chronic kidney disease (CKD).

methodsA retrospective cohort study was conducted using TriNetX, including patients aged 18-50. Two primary cohorts were defined: obese patients with CKD on GLP-1RAs ≥ 1 year (CKD+/GLP-1RA+) and obese patients with CKD not on GLP-1RAs (CKD+/GLP-1RA-). A subgroup analysis compared CKD+/GLP-1RA + patients to obese patients without CKD on GLP-1RAs (CKD-/GLP-1RA+). Primary outcomes were upper and lower limb fractures. Risk analysis and Kaplan-Meier survival analysis assessed fracture incidence over 5 years.

resultsAfter matching, 13 441 patients were included per cohort. CKD+/GLP-1RA + patients had fewer fractures than CKD+/GLP-1RA- patients (Risk Difference: -0.016, 95% CI: -0.018, -0.013; RR: 0.196, 95% CI: 0.145, 0.265; OR: 0.193, 95% CI: 0.143, 0.261), with higher fracture-free survival (99.31% vs. 95.47%; p < 0.001). Subgroup analysis (13 723 patients per cohort) showed CKD+/GLP-1RA + patients had a slightly higher fracture risk than CKD-/GLP-1RA + patients (Risk Difference: 0.003, 95% Cl: 0.001, 0.004; RR: 2.357, 95% Cl: 1.516, 3.665; OR: 2.364, 95% Cl: 1.518, 3.680), with lower fracture-free survival (98.87% vs. 99.19%; p < 0.001).

conclusionThese findings suggest a possible CKD-associated modification on the skeletal effects of GLP-1RAs, implicating that CKD patients' bone health should be monitored during GLP-1RA treatment.

Indexed as

Diabetes Mellitus, Type 2Fractures, BoneGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsObesityRenal Insufficiency, ChronicAdolescentAdultFemaleHumansIncidenceKaplan-Meier EstimateMaleMiddle AgedRetrospective StudiesRisk FactorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agentschronic kidney disease (CKD)fracture riskGLP‐1 receptor agonistsobesity

Identifiers

PMID41995433
PMCPMC13421053

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.